GRAIL, Inc. (NASDAQ:GRAL)
| Market Cap | 6.42B+78.0% |
| Revenue (ttm) | 166.60M+17.5% |
| Net Income | -406.18M+0.0% |
| EPS | -9.50+18.3% |
| Shares Out | 44.67M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 752,545 |
| Open | 139.35 |
| Previous Close | 139.44 |
| Day's Range | 132.17 - 143.82 |
| 52-Week Range | 41.50 - 166.48 |
| Beta | 3.25 |
| Analysts | Buy |
| Price Target | 107.88(-24.91%) |
| Earnings Date | Feb 18, 2027 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About GRAL
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
7 firms rating GRAL in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 18, 2027Earnings report
Ask Barron about GRAL
$GRAL stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in GRAL holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by GRAL's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
GRAL Estimated quarterly lobbying spending
Source: U.S. Senate LDA
GRAL Revenue by Segment or Geography
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New GRAL patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to GRAL from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in GRAL
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $182.47M |
| IWMiShares Russell 2000 ETF | $147.43M |
| XBIState Street SPDR S&P Biotech ETF | $142.66M |
| VXFVanguard Extended Market ETF | $70.51M |
| IWNiShares Russell 2000 Value ETF | $54.16M |
| IBBiShares Biotechnology ETF | $44.80M |
Estimated from each fund’s disclosed top holdings × AUM
GRAL Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from GRAL’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
Healthcare: 51 sector peers carry a ranked score; this one has no qualifying buying in the window · sector average 66.9
What’s Behind the Score
News check: FDA panel backing for Galleri cancer test and Canada expansion provide positive catalysts; growth potential offset by cash burn concerns.
Recent Insider Activity
Insider Score Trend Over Time
+0.0 since Sep 1Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.